About US
Contact us
-
BeiGene's Brukinsa turns in 'near best case scenario' against Imbruvica in key CLL trial: analystBeiGene’s argument for its BTK inhibitor Brukinsa is that it’s a better drug than AbbVie and Johnson & Johnson’s first-to-market Imbruvica in terms of both efficacy and safety. Now, it appears to2021/4/26
-
Forget the competition. Sanofi still plans to usher its COVID-19 shot across the finish lineOneof the topvaccine playersopted to call it quits on its COVID-19 research after delays and setbacks. There are plenty of options already on the market or close to it. But not Sanofi. The French dru2021/4/26
-
Seagen, Astellas eye fast FDA review for Padcev's expanded bladder cancer use, with all-important Keytruda combo data to comeSeagen and Astellas have stepped in the FDA fast lane to move Padcev into earlier bladder cancer treatment—and one step closer to the antibody-drug conjugate’s blockbuster forecast. The FDAputtwo Pad2021/4/21
-
As variants take hold, FDA revokes authorization of Eli Lilly's solo COVID-19 antibodyEli Lilly’s COVID-19 neutralizing antibody drug was the first of its kind to score FDA authorization against the illness in early November. Emerging coronavirus variants later threatened to mute the2021/4/21
-
With the competition struggling, Pfizer's COVID vaccine sales could hit $24B this year: analystMessenger RNA COVID-19 vaccines are sailing along as viral vector shots encounter setback after setback. How will the recent headlinesaffect vaccine sales in 2021? In his weekly notes to investors, B2021/4/19
-
Lower Libtayo's price before Chinese PD-1s do, says analyst in open letter to Regeneron CEORegeneron and partner Sanofi recently snagged an FDA nod for Libtayo in the large and lucrative indication of newly diagnosed non-small cell lung cancer (NSCLC). And one analyst is already asking the2021/4/19
-
Moderna eyes beefed-up vaccine production with the help of U.S.-brokered manufacturing talks: reportThe feds already had a hand in Merck and Johnson & Johnson's "wartime" COVID-19 production pact. Now, Moderna is reportedly in government-brokered talks with a potential manufacturing partner. Mo2021/4/16
-
Novartis inks 3rd COVID-19 production pact, this time for Roche's arthritis med ActemraNovartis wasn’t kidding when it said it wanted to help with the global COVID-19 fight earlier this year. The company racked up back-to-back manufacturing pacts with Pfizer-BioNTech and CureVac,and, n2021/4/16
-
With crucial EU launch rolling, Amarin's Thero hands CEO baton to new European commercial chiefJust as Amarin’s heart drug Vascepa begins its make-or-break European launch, the company is changing leadership at the top. The move adds uncertainty to the mix, one analyst said, and tones down the2021/4/14
-
Feds call halt to Johnson & Johnson COVID-19 vaccine rollout after 'extremely rare' blood clot casesAfter drug regulators on both sides of the Atlantic revealed safety probes into Johnson & Johnson’s COVID-19 vaccine, U.S. officials arecalling for an immediate pauseto the rollout. Since the vac2021/4/14